Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MRK

Merck & Co Inc

Sep 17 • 04:00PM ET

118.29

Dollar change +0.33
Percentage change 0.28	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VOO SPY IVV VTV XLV VIG VYM IWF VHT

Scroll to Statements

Index	DJIA, S&P 500	P/E	21.92	EPS (ttm)	5.40	Insider Own	0.10%	Shs Outstand	2.53B	Perf Week	2.57%
Market Cap	299.84B	Forward P/E	12.15	EPS next Y	9.74	Insider Trans	0.00%	Shs Float	2.53B	Perf Month	4.06%
Income	13.74B	PEG	-	EPS next Q	1.74	Inst Own	78.78%	Short Float	1.02%	Perf Quarter	-7.22%
Sales	62.19B	P/S	4.82	EPS this Y	431.22%	Inst Trans	0.64%	Short Ratio	2.64	Perf Half Y	-2.59%
Book/sh	17.19	P/B	6.88	EPS next Y	21.37%	ROA	12.65%	Short Interest	25.91M	Perf Year	10.02%
Cash/sh	4.50	P/C	26.31	EPS next 5Y	-	ROE	33.39%	52W Range	99.14 - 134.63	Perf YTD	8.50%
Dividend Est.	3.14 (2.65%)	P/FCF	22.81	EPS past 5Y	-42.70%	ROI	17.54%	52W High	-12.14%	Beta	0.41
Dividend TTM	3.08 (2.60%)	Quick Ratio	1.22	Sales past 5Y	7.72%	Gross Margin	72.33%	52W Low	19.32%	ATR (14)	2.30
Dividend Ex-Date	Sep 16, 2024	Current Ratio	1.47	EPS Y/Y TTM	340.50%	Oper. Margin	26.04%	RSI (14)	54.94	Volatility	1.53% 1.72%
Employees	72000	Debt/Eq	0.87	Sales Y/Y TTM	8.43%	Profit Margin	22.09%	Recom	1.42	Target Price	140.05
Option/Short	Yes / Yes	LT Debt/Eq	0.80	EPS Q/Q	191.12%	Payout	2065.60%	Rel Volume	0.61	Prev Close	117.96
Sales Surprise	1.53%	EPS Surprise	5.17%	Sales Q/Q	7.25%	Earnings	Jul 30 BMO	Avg Volume	9.80M	Price	118.29
SMA20	1.62%	SMA50	-0.41%	SMA200	-3.06%	Trades		Volume	5,945,410	Change	0.28%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-24	Downgrade	Societe Generale	Hold → Sell	$104
Jan-04-24	Upgrade	TD Cowen	Market Perform → Outperform	$125 → $135
Nov-09-23	Initiated	Deutsche Bank	Buy	$115
Oct-27-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$132
Oct-20-23	Upgrade	UBS	Neutral → Buy	$117 → $122
Jul-14-23	Initiated	HSBC Securities	Hold	$123
Apr-13-23	Upgrade	Citigroup	Neutral → Buy	$105 → $130
Mar-28-23	Downgrade	Societe Generale	Buy → Hold
Mar-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$120 → $115
Mar-06-23	Initiated	Jefferies	Buy	$125
Feb-22-23	Upgrade	Wolfe Research	Peer Perform → Outperform	$127
Jan-04-23	Upgrade	BofA Securities	Neutral → Buy	$110 → $130
Nov-18-22	Initiated	Credit Suisse	Outperform	$120
Oct-10-22	Upgrade	Guggenheim	Neutral → Buy
Sep-14-22	Upgrade	Berenberg	Hold → Buy	$95 → $100
Jul-06-22	Upgrade	Daiwa Securities	Neutral → Buy	$89 → $102
Jun-06-22	Resumed	SVB Leerink	Outperform	$102
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$80
Dec-17-21	Initiated	Goldman	Buy	$93
Dec-16-21	Initiated	Daiwa Securities	Neutral	$70

Show Previous Ratings

Today 07:58AM	Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study (Benzinga)
07:51AM	ADC developed by Daiichi, Merck outperforms chemo in lung cancer trial (BioPharma Dive)
06:00AM	Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial (Business Wire)
Sep-16-24 07:00AM	BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 (GlobeNewswire)
Sep-15-24 10:30AM	KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) (Business Wire)
08:45AM	Loading…
08:45AM	Ten-Year Data for Merck's KEYTRUDA (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma (Business Wire)
Sep-14-24 12:40PM	Is Merck & Co. (MRK) the Best Blue Chip Stock To Invest In According to Short Sellers? (Insider Monkey)
10:47AM	Merck & Co., Inc. (MRK): A Good Beginner Stock According to Analysts (Insider Monkey)
10:35AM	KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (Business Wire)
10:30AM	Mercks KEYTRUDA (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer (Business Wire)
08:10AM	TIGIT drug from iTeos shrinks lung tumors in trial (BioPharma Dive)
03:15AM	KEYTRUDA (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma (Business Wire)
Sep-12-24 03:10PM	Moderna Cost Cuts Fail to Restore Investor Trust (The Wall Street Journal)
07:00AM	Health Canada Approves KEYTRUDA® as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prior treatment and who have no satisfactory alternative treatment options (PR Newswire)
12:25AM	Is Merck & Co., Inc. (MRK) the Best Defensive Stock According to Reddit? (Insider Monkey)
06:45AM	Loading…
Sep-11-24 06:45AM	Merck to Participate in the Bank of America 2024 Global Healthcare Conference (Business Wire)
06:30AM	Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males (Business Wire)
Sep-09-24 01:55PM	A Better Drug Than Mercks Blockbuster Keytruda? Not So Fast (The Wall Street Journal)
09:59AM	Merck stock falls on Summit cancer drug's trial results (Yahoo Finance Video)
08:02AM	Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half (Benzinga)
Sep-07-24 11:30AM	Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial (Business Wire)
Sep-06-24 06:14PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
12:10PM	7-Eleven's Owner Turned Down a Takeover Bid But It's Open to Offers (Investopedia)
Sep-05-24 07:00AM	Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan) (PR Newswire)
04:32AM	MSD and EyeBio launch trial of Restoret for diabetic macular oedema (Clinical Trials Arena)
Sep-04-24 03:00PM	WINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension (PR Newswire)
06:45AM	Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024 (Business Wire)
06:40AM	Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret for the Treatment of Diabetic Macular Edema (Business Wire)
04:12AM	EC approves Mercks Keytruda-Padcev combo for urothelial cancer (Pharmaceutical Technology)
Sep-03-24 11:32PM	Is Merck & Co., Inc. (MRK) the Best Cancer Stock to Buy Now? (Insider Monkey)
01:22PM	Loading…
01:22PM	Heard on the Street: Pfizer Better Watch Out for This Biotech (The Wall Street Journal)
09:40AM	Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher (Benzinga)
08:10AM	Vaxcytes best-case data for pneumococcal vaccine boost shares (BioPharma Dive)
06:45AM	European Commission Approves Mercks KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults (Business Wire)
Aug-29-24 10:35AM	Merck Pulls Plug On Two Keytruda Late-Stage Studies On Underwhelming Data (Benzinga)
09:33AM	MSD discontinues two Phase III Keytruda trials (Clinical Trials Arena)
07:30AM	Keytruda fails lung and skin cancer trials, limiting further expansion (BioPharma Dive)
06:45AM	Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
06:30AM	Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials (Business Wire)
Aug-28-24 04:52AM	MSD commences Phase III trial of thrombocythemia treatment (Clinical Trials Arena)
Aug-27-24 08:52AM	Do Options Traders Know Something About Merck (MRK) Stock We Don't? (Zacks)
07:35AM	RA Capital-backed startup raises $100M; UCB sells China business (BioPharma Dive)
06:45AM	Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia (Business Wire)
05:32AM	GI Innovation and MSD partner for trial of GI-102 and Keytruda regimen for cancer (Clinical Trials Arena)
Aug-26-24 03:22PM	MSD snags European approval for pulmonary arterial hypertension therapy (Pharmaceutical Technology)
12:00PM	Merck & Co., Inc. (MRK): A Good Undervalued Stock to Invest In Now (Insider Monkey)
06:45AM	Merck Receives European Commission Approval for WINREVAIR (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III (Business Wire)
Aug-23-24 02:10PM	Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer (Benzinga)
09:00AM	Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock (Zacks)
Aug-22-24 07:00AM	Health Canada Approves KEYTRUDA® for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC, in combination with enfortumab vedotin (PR Newswire)
Aug-21-24 09:29AM	Jim Cramer Says He Has Tremendous Faith Merck (MRK) CEO (Insider Monkey)
Aug-19-24 08:04AM	7-Eleven Operator Considers Takeover by Circle K Owner (Investopedia)
Aug-17-24 03:21PM	Merck & Co., Inc. (MRK): The Best Defensive Stock Now According to Hedge Funds? (Insider Monkey)
Aug-16-24 08:54PM	Merck & Co., Inc. (MRK): Hedge Funds Are Bullish on This Diabetes Stock Now (Insider Monkey)
06:09PM	10 Best Defensive Stocks To Buy Now (Insider Monkey)
Aug-15-24 05:30PM	These 10 drugs will be cheaper after Medicare negotiations (Yahoo Finance Video)
12:34PM	Medicare negotiates lower prices for 10 high-cost drugs (Yahoo Finance Video)
10:49AM	Big Pharma: The government revealed its list of negotiated drug prices. Here are the reactions. (Yahoo Finance)
07:49AM	Medicare to save $6B in 2026 from the first ever Part D drug pricing negotiations (Yahoo Finance)
Aug-14-24 06:15AM	3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct (InvestorPlace)
Aug-09-24 03:33PM	MSD sets sights on bispecific antibody market with Curon acqusition (Pharmaceutical Technology)
03:18PM	Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst (Benzinga)
08:09AM	Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion (The Wall Street Journal)
06:45AM	Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical (Business Wire)
06:32AM	MSD discontinues Phase III KeyVibe-008 trial for lung cancer treatment (Clinical Trials Arena)
05:59AM	Merck bets $700M on an antibody drugs potential in immune diseases (BioPharma Dive)
Aug-08-24 12:23PM	Merck TIGIT drug fails another trial; Intellia therapy succeeds in HAE study (BioPharma Dive)
09:00AM	Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know (Zacks)
06:45AM	Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer (Business Wire)
Aug-07-24 07:57AM	Amgen talks obesity drug differentiation; Servier brain cancer drug approved by FDA (BioPharma Dive)
Aug-06-24 09:00AM	Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities (GlobeNewswire)
06:45AM	Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070 (Business Wire)
Aug-02-24 06:00PM	How To Earn $100 Per Month From Merck Stock (Benzinga)
02:22PM	What Are the Hottest Biotech Stocks Right Now? 3 Top Picks. (InvestorPlace)
Aug-01-24 08:00AM	IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer (Business Wire)
Jul-31-24 09:53AM	Revenue growth for 13 of top 20 biopharmas with obesity drug successes in 2023 (Pharmaceutical Technology)
07:33AM	Vertexs pain drug gets speedy FDA review; Keytruda hits a sales milestone (BioPharma Dive)
03:20AM	Heard on the Street Tuesday Recap: Fed Purgatory (The Wall Street Journal)
01:58AM	Q2 2024 Merck & Co Inc Earnings Call (Thomson Reuters StreetEvents)
Jul-30-24 02:15PM	Merck (MRK) Q2 2024 Earnings Call Transcript (Motley Fool) -9.81%
01:30PM	Big movers: NVIDIA slumps; P&G, Merck down, PayPal up (TheStreet)
12:09PM	Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer (Benzinga)
12:05PM	Why this analyst is 'extremely bullish' on biopharma (Yahoo Finance Video)
12:00PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
11:40AM	Merck Stock Slides on Lowered Adjusted EPS Guidance (Investopedia)
11:25AM	Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View (Zacks)
10:54AM	Stock Market Today: Stock Market News And Analysis (Investor's Business Daily)
10:36AM	Merck Shares Fall After Drugmaker Cuts 2024 Outlook (The Wall Street Journal)
10:35AM	Merck Falls as HPV Vaccine Miss Overshadows Profit, Sales Beat (Bloomberg)
10:09AM	Q2 earnings: Has Pfizer bucked declining COVID business? (Yahoo Finance Video)
08:45AM	Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast (Benzinga)
07:17AM	JetBlue, Pfizer earnings, Delta reportedly goes after CrowdStrike: Yahoo Finance (Yahoo Finance Video)
06:45AM	Merck: Q2 Earnings Snapshot (Associated Press Finance)
06:32AM	Merck second quarter tops Street view on strong Keytruda sales (Reuters)
06:32AM	Concern over Merck's Gardasil sales in China sink shares (Reuters)
06:30AM	Merck Announces Second-Quarter 2024 Financial Results (Business Wire)
03:28AM	Pfizer, JetBlue, PayPal rise premarket; Merck, CrowdStrike, Diageo fall (Investing.com)
Jul-26-24 06:50AM	Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma (Business Wire)
Jul-24-24 05:12AM	MSD reports positive topline data from Phase IIb/III RSV trial in infants (Clinical Trials Arena)
Jul-23-24 03:04PM	Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants (Benzinga)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Guindo Chirfi	Chief Marketing Officer	Aug 05 '24	Option Exercise	115.20	36,901	4,250,995	57,782	Aug 06 12:20 PM
Smart Dalton	SVP Fin. - Global Controller	May 03 '24	Option Exercise	128.26	2,046	262,420	4,708	May 06 04:10 PM
Smart Dalton	SVP Fin. - Global Controller	May 04 '24	Option Exercise	127.51	612	78,036	4,730	May 06 04:10 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	May 04 '24	Option Exercise	127.51	27,126	3,458,836	163,720	May 06 04:08 PM
Klobuchar Michael A	EVP - Chief Strategy Officer	May 04 '24	Option Exercise	127.51	887	113,101	24,058	May 06 04:06 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	May 04 '24	Option Exercise	127.51	912	116,289	24,271	May 06 04:01 PM
Romanelli Joseph	President, Human Health Int?l	May 02 '24	Option Exercise	128.80	2,262	291,346	21,831	May 02 04:29 PM
Smart Dalton	SVP Fin. - Global Controller	May 02 '24	Option Exercise	128.80	381	49,073	3,048	May 02 04:23 PM
Merck & Co., Inc.	10% Owner	Mar 11 '24	Buy	23.00	21,397,205	492,135,715	1,000	Mar 11 03:27 PM
Litchfield Caroline	EVP & CFO	Feb 14 '24	Option Exercise	58.08	38,291	2,223,941	89,199	Feb 15 04:03 PM
Litchfield Caroline	EVP & CFO	Feb 14 '24	Sale	125.50	38,291	4,805,520	50,908	Feb 15 04:03 PM
Davis Robert M	Chairman, CEO & President	Feb 13 '24	Option Exercise	74.18	150,000	11,127,160	498,327	Feb 15 04:01 PM
Davis Robert M	Chairman, CEO & President	Feb 14 '24	Option Exercise	73.73	85,021	6,268,598	433,348	Feb 15 04:01 PM
Davis Robert M	Chairman, CEO & President	Feb 13 '24	Sale	125.85	150,000	18,877,424	348,327	Feb 15 04:01 PM
Davis Robert M	Chairman, CEO & President	Feb 14 '24	Sale	125.40	85,021	10,661,574	348,327	Feb 15 04:01 PM
Romanelli Joseph	President, Human Health Int?l	Feb 13 '24	Sale	124.89	1,000	124,888	19,569	Feb 14 04:03 PM
Li Dean Y	Executive VP & President, MRL	Feb 09 '24	Option Exercise	62.07	14,702	912,553	60,944	Feb 12 04:03 PM
Li Dean Y	Executive VP & President, MRL	Feb 09 '24	Sale	125.50	14,702	1,845,083	46,242	Feb 12 04:03 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 07 '24	Sale	127.57	1,451	185,108	19,812	Feb 08 04:04 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 02 '24	Option Exercise	78.80	20,937	1,649,906	42,286	Feb 05 04:01 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 02 '24	Sale	127.17	18,959	2,411,111	23,327	Feb 05 04:01 PM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 02 '24	Option Exercise	73.65	32,994	2,430,159	74,313	Feb 02 04:07 PM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 02 '24	Sale	126.65	50,694	6,420,349	23,619	Feb 02 04:07 PM
Zachary Jennifer	EVP, General Counsel	Feb 02 '24	Option Exercise	87.10	19,417	1,691,221	78,557	Feb 02 04:05 PM
Zachary Jennifer	EVP, General Counsel	Feb 02 '24	Sale	126.97	49,499	6,284,779	29,058	Feb 02 04:05 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Nov 09 '23	Sale	102.38	2,081	213,061	18,191	Nov 13 07:36 AM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Nov 08 '23	Sale	105.03	43,823	4,602,668	111,764	Nov 09 09:04 AM
Oosthuizen Johannes Jacobus	President, U.S. Market	Oct 30 '23	Option Exercise	102.82	915	94,080	20,723	Oct 31 11:08 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK

Merck & Co Inc

Upgrade your FINVIZ experience